Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma

- Mercieca-Bebber, R., Barnes, E. H., Leung, J., Wang, T., Bohmer, R., Cameron, D., Simes, J., Gebski, V., Smithers, M., Thomas, J., Zalcberg, J., Barbour, A. P., Wilson, K., Samoon, Z., Walpole, E., Mai, T., Ackland, S., Burge, M., Dickie, G., Watson, D.

Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial

- Barbour, A. P., Walpole, E. T., Mai, G. T., Barnes, E. H., Watson, D. I., Ackland, S. P., Martin, J. M., Burge, M., Finch, R., Karapetis, C. S., Shannon, J., Nott, L. M., Varma, S., Marx, G., Falk, G. L., Gebski, V., Oostendorp, M., Wilson, K., Thomas, J., Lampe, G.